Download PDF

Clinical Trial Results:
A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults

Summary
EudraCT number	2020-001038-36
Trial protocol	DE
Global end of trial date	13 Apr 2022

Results information
Results version number	v1(current)
This version publication date	27 Apr 2023
First version publication date	27 Apr 2023
Other versions

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

BNT162-01

ISRCTN number

US NCT number

NCT04380701

WHO universal trial number (UTN)

U1111-1249-4220

Sponsor organisation name

BioNTech SE

Sponsor organisation address

An der Goldgrube 12, Mainz, Germany, 55131

Public contact

BioNTech clinical trials patient information, BioNTech SE, 0049 613190840, patients@biontech.de

Scientific contact

BioNTech clinical trials patient information, BioNTech SE, 0049 613190840, patients@biontech.de

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Analysis stage

Final

Date of interim/final analysis

05 Sep 2022

Is this the analysis of the primary completion data?

Global end of trial reached?

Yes

Global end of trial date

13 Apr 2022

Was the trial ended prematurely?

Main objective of the trial

To describe the safety and tolerability profiles of prophylactic BNT162 vaccines in healthy adults after single dose (SD; prime only) or prime/boost (P/B) immunization.

Protection of trial subjects

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy

Evidence for comparator

Actual start date of recruitment

23 Apr 2020

Long term follow-up planned

Independent data monitoring committee (IDMC) involvement?

Number of subjects enrolled per country

Country: Number of subjects enrolled

Germany: 512

Worldwide total number of subjects

512

EEA total number of subjects

512

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

Children (2-11 years)

Adolescents (12-17 years)

Adults (18-64 years)

434

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

Study participants were selected from the volunteer panel at the clinical CRO, volunteers who responded to either generic or study-specific advertisements in social media, or volunteers who contacted the clinical CRO via a web-based study participant recruitment portal.

Screening details

Study participants were selected from this pool of volunteers according to inclusion and exclusion criteria. The first participant was enrolled on 23 APR 2020. All enrolled participants were allocated to treatment.

Period 1 title

Overall Study (overall period)

Is this the baseline period?

Yes

Allocation method

Not applicable

Blinding used

Not blinded

Are arms mutually exclusive

Yes

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Arm description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162a1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular (IM); upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Arm description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162a1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

Arm description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee [SRC]).

Arm type

Experimental

Investigational medicinal product name

BNT162a1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the SRC).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

Arm description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b1

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), Immunocompromised participants (ICP) expansion cohort (Cohort 13).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen), ICP expansion cohort (Cohort 13). PT = post-transplant.

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), alternative posology dose group expansion cohort (Cohort 11).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), adaptive immune response dose group expansion cohort (C12 = Cohort 12).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14

Arm description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), B-cell immune response dose group expansion cohort (C14 = Cohort 14).

Arm type

Experimental

Investigational medicinal product name

BNT162b2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. For the P/B regimens, use of the same arm for both doses was allowed. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (single dose [SD] regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. The non-dominant arm was preferred.

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD

Arm description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Arm type

Experimental

Investigational medicinal product name

BNT162c2

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

IM; upper arm, musculus deltoideus. The non-dominant arm was preferred.

Number of subjects in period 1	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Started	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	15	15	30	90	20	12	12	12	12	12	12	12	12
Completed end of treatment phase	12	12	6	12	12	11	10	11	11	12	12	12	12	11	12	11	12	12	12	12	12	15	15	30	89	19	12	12	12	11	12	12	11	12
Completed	12	12	6	12	12	11	10	11	11	11	12	11	12	11	12	11	11	12	12	11	11	0	0	0	0	19	12	12	12	10	12	12	11	11
Not completed	0	0	0	0	0	1	2	1	1	1	0	1	0	1	0	1	1	0	0	1	1	15	15	30	90	1	0	0	0	2	0	0	1	1
Adverse event, serious fatal	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-
Consent withdrawn by subject	-	-	-	-	-	-	1	1	-	-	-	1	-	1	-	-	1	-	-	-	-	-	2	2	1	1	-	-	-	-	-	-	-	-
Physician decision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	-	-	-	-
Adverse event, non-fatal	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	1	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Roll-over into trial BNT162-14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	11	10	31	-	-	-	-	-	-	-	-	-
Non-trial SARS-COV-2 vaccination due to COVID-19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	2	16	55	-	-	-	-	-	-	-	-	-
Pregnancy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Private reason(s)	-	-	-	-	-	-	1	-	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	-	-	-	-
Lost to follow-up	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	-	-	1	-	-	-	1

Baseline characteristics

Top of page

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen).

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee [SRC]).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the SRC).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), Immunocompromised participants (ICP) expansion cohort (Cohort 13).

Reporting group title

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen), ICP expansion cohort (Cohort 13). PT = post-transplant.

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), alternative posology dose group expansion cohort (Cohort 11).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12

Reporting group description

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), B-cell immune response dose group expansion cohort (C14 = Cohort 14).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (single dose [SD] regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group values	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD	Total
Number of subjects	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	15	15	30	90	20	12	12	12	12	12	12	12	12	512
Age categorical
Units: Subjects
Age continuous
Units: years
arithmetic mean (standard deviation)	50.80 ± 2.58	48.31 ± 9.04	38.22 ± 13.87	38.21 ± 10.48	41.44 ± 11.27	43.62 ± 11.03	39.42 ± 11.41	35.74 ± 8.60	33.88 ± 10.72	35.81 ± 12.50	64.31 ± 5.89	65.66 ± 5.95	67.16 ± 6.47	36.65 ± 10.14	39.64 ± 10.14	35.07 ± 10.46	42.75 ± 9.89	47.21 ± 6.43	65.44 ± 7.42	65.88 ± 6.56	63.87 ± 5.42	48.04 ± 10.36	48.93 ± 11.87	51.92 ± 13.57	55.59 ± 16.07	48.45 ± 13.87	36.42 ± 10.33	39.41 ± 12.34	34.47 ± 10.24	35.42 ± 9.68	40.03 ± 14.67	35.23 ± 11.88	42.40 ± 12.04	32.60 ± 10.87	-
Gender categorical
Units: Subjects
Female	5	6	1	7	6	8	4	4	6	5	5	10	8	5	7	8	10	4	4	6	8	3	9	13	45	10	8	5	3	8	10	8	5	7	261
Male	7	6	5	5	6	4	8	8	6	7	7	2	4	7	5	4	2	8	8	6	4	12	6	17	45	10	4	7	9	4	2	4	7	5	251
Ethnicity
Units: Subjects
Hispanic or Latino	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	1	0	0	6
Not Hispanic or Latino	12	12	6	11	12	12	12	12	12	11	12	12	12	12	12	12	12	12	12	12	12	15	15	30	89	20	12	12	10	12	12	11	12	12	506
Race
Units: Subjects
Asian	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	1	0	0	6
Black or African American	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2
White	12	12	5	12	12	11	11	12	12	11	12	12	12	12	12	12	12	12	12	12	12	14	15	30	89	19	11	11	12	12	12	11	12	12	502
More than one race	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
Unknown or Not Reported	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Weight
Units: kilogram(s)
arithmetic mean (standard deviation)	77.68 ± 7.59	72.54 ± 10.85	78.58 ± 14.93	72.99 ± 14.79	77.11 ± 14.07	71.57 ± 14.09	73.58 ± 11.88	79.84 ± 13.81	76.73 ± 13.32	78.70 ± 13.85	71.90 ± 10.98	70.38 ± 9.14	69.98 ± 8.06	80.18 ± 14.13	77.08 ± 10.84	76.11 ± 11.67	72.45 ± 10.97	77.78 ± 8.43	77.87 ± 9.78	76.91 ± 12.38	75.80 ± 11.98	73.85 ± 9.67	73.50 ± 10.07	77.79 ± 12.92	75.44 ± 13.02	79.09 ± 14.94	67.45 ± 13.53	76.41 ± 15.66	72.44 ± 6.86	70.94 ± 11.43	63.75 ± 6.14	73.26 ± 15.39	73.48 ± 9.51	68.90 ± 11.56	-
Body mass index
Units: kilogram(s)/square metre
arithmetic mean (standard deviation)	24.61 ± 3.14	24.23 ± 2.78	24.73 ± 2.63	25.17 ± 2.89	24.94 ± 2.68	24.20 ± 2.32	24.34 ± 2.33	25.68 ± 3.44	25.52 ± 3.50	25.19 ± 3.09	24.73 ± 2.46	25.59 ± 2.22	25.63 ± 2.22	25.25 ± 3.26	25.50 ± 2.79	25.13 ± 2.07	25.43 ± 2.34	25.01 ± 1.38	25.43 ± 2.15	25.62 ± 2.47	25.85 ± 2.75	23.62 ± 1.90	25.63 ± 2.82	25.53 ± 2.72	25.08 ± 2.73	26.12 ± 2.96	23.31 ± 2.38	25.02 ± 2.85	23.83 ± 2.39	25.06 ± 3.73	22.82 ± 1.54	24.97 ± 3.17	24.19 ± 2.04	24.04 ± 2.59	-

End points

Top of page

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen).

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee [SRC]).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the SRC).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), Immunocompromised participants (ICP) expansion cohort (Cohort 13).

Reporting group title

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen), ICP expansion cohort (Cohort 13). PT = post-transplant.

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), alternative posology dose group expansion cohort (Cohort 11).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12

Reporting group description

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), B-cell immune response dose group expansion cohort (C14 = Cohort 14).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (single dose [SD] regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose

Top of page

End point title

Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose ^[1]

End point description

Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Safety Set - all participants who received at least one dose of the IMP. 'Prime to D7' below indicates Prime up to Day 7 after Prime, 'Boost to D7' below indicates Boost up to Day 7 after Boost. 999 indicates data not available as the boost immunization was withheld for the BNT162a1 3 μg cohort and the BNT162b1 60 μg younger cohort following Safety Review Committee (SRC) decision. 9999 indicates data not available as the boost immunization was not administered to the BNT162c2 SD regimen cohorts.

End point type

Primary

End point timeframe

From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)

Notes
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis was planned for this endpoint.

End point values	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Number of subjects analysed	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	15	15	30	90	20	12	12	12	12	12	12	12	12
Units: Participants
Prime to D7: any local reaction	9	11	6	6	5	10	12	11	12	12	7	11	11	6	9	12	12	10	7	9	9	12	14	16	82	20	4	3	8	11	4	7	5	11
Prime to D7: any severe/grade ≥3 local reaction	0	0	0	0	0	1	2	4	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Boost to D7: any local reaction	3	10	999	7	5	10	11	11	11	999	8	9	9	4	8	10	10	11	7	8	10	12	11	27	79	19	3	5	7	8	9999	9999	9999	9999
Boost to D7: any severe/grade ≥3 local reaction	0	0	999	2	0	0	0	2	3	999	0	0	0	0	0	0	0	0	1	0	1	0	0	2	2	1	0	0	0	0	9999	9999	9999	9999

No statistical analyses for this end point

Primary: Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose

Top of page

End point title

Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose ^[2]

End point description

Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Safety Set - all participants who received at least one dose of the IMP. Prime to D7 below indicates Prime up to Day 7 after Prime, Boost to D7 below indicates Boost up to Day 7 after Boost. 999 indicates data not available as the boost immunization was withheld for the BNT162a1 3 μg cohort and the BNT162b1 60 μg younger cohort following SRC decision. 9999 indicates data not available as the boost immunization was not administered to the BNT162c2 SD regimen cohorts.

End point type

Primary

End point timeframe

From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)

Notes
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis was planned for this endpoint.

End point values	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Number of subjects analysed	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	15	15	30	90	20	12	12	12	12	12	12	12	12
Units: Participants
Prime to D7: any local reaction	6	12	6	9	8	8	11	11	12	12	9	10	11	9	9	12	9	9	3	4	9	12	14	12	68	15	5	8	9	12	7	7	4	8
Prime to D7: any severe/grade ≥3 local reaction	1	1	5	0	0	1	2	3	5	8	1	1	2	0	0	0	1	0	1	0	0	1	0	0	5	0	0	0	1	1	0	2	0	2
Boost to D7: any local reaction	3	12	999	7	7	9	10	11	11	999	8	10	12	4	2	7	10	10	4	8	11	13	12	21	78	16	3	7	6	9	9999	9999	9999	9999
Boost to D7: any severe/grade ≥3 local reaction	0	4	999	3	1	5	5	6	5	999	2	2	4	0	0	1	1	3	1	0	2	4	1	4	14	3	1	1	0	2	9999	9999	9999	9999

No statistical analyses for this end point

Primary: The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1

Top of page

End point title

The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1 ^[3]

End point description

TEAEs without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade ≥3 TEAE) using the Safety Set. Safety Set - all participants who received at least one dose of the IMP.

End point type

Primary

End point timeframe

28 days following Dose 1 or up to Dose 2 (whichever was first)

Notes
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis was planned for this endpoint.

End point values	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Number of subjects analysed	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	15	15	30	90	20	12	12	12	12	12	12	12	12
Units: Percentage of participants
number (not applicable)
Any TEAE	8	33	83	8	0	50	33	42	42	58	25	17	58	25	50	50	8	42	25	33	25	7	53	13	26	35	17	33	17	17	50	58	25	25
Any grade ≥3 TEAE	0	0	0	0	0	0	8	0	0	0	8	8	8	0	0	8	0	0	0	0	17	0	7	0	2	5	0	0	0	8	0	0	0	0

No statistical analyses for this end point

Primary: The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)

Top of page

End point title

The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2) ^[4] ^[5]

End point description

TEAEs, without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade ≥3 TEAE) using the Safety Set. Safety Set - all participants who received at least one dose of the IMP.

End point type

Primary

End point timeframe

28 days following Dose 2 or Dose 1 (if no Dose 2 was given)

Notes
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis was planned for this endpoint.
[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for the BNT162c2 Single Dose Cohorts are not reported for this endpoint as no Boost dose was planned.

End point values	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg
Number of subjects analysed	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	15	15	30	90	20	12	12	12	12
Units: Percentage of participants
number (not applicable)
Any TEAE	17	33	83	58	8	75	50	58	67	58	25	33	75	58	58	67	25	50	33	58	33	13	73	40	49	45	33	42	33	17
Any grade ≥3 TEAE	0	0	0	0	0	0	25	0	0	0	8	8	17	0	0	8	0	8	8	8	17	0	7	3	4	10	0	8	0	8

No statistical analyses for this end point

Secondary: Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Top of page

End point title

Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B) ^[6]

End point description

At Day 1 (Baseline) and at 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one postbaseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as Day 29 and/or Day 50 were scheduled before approval of protocol version 7 which implemented these visits. 999 indicates confidence interval not calculated as values of at least 3 participants were not available.

End point type

Secondary

End point timeframe

Up to 183 days following Dose 1

Notes
[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162a1, BNT162b1, BNT162b2 Dose Ranging, and BNT162c2 Prime/Boost Cohorts.

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

Number of subjects analysed

Units: Titer

geometric mean (confidence interval 95%)

Pre-Prime Immunization (Day 1)

5.0 (5.0 to 5.0)

5.1 (4.8 to 5.5)

5.0 (5.0 to 5.0)

6.9 (3.4 to 13.8)

5.0 (5.0 to 5.0)

7 days after Prime Immunization (Day 8)

5.0 (5.0 to 5.0)

5.1 (4.8 to 5.5)

5.0 (5.0 to 5.0)

8.2 (2.8 to 24.1)

5.0 (5.0 to 5.0)

21 days after Prime Immunization (Day 22)

5.0 (5.0 to 5.0)

10.0 (6.1 to 16.3)

6.9 (4.4 to 10.7)

10.0 (5.4 to 18.5)

11.7 (6.2 to 22.1)

29.1 (13.5 to 63.0)

20.6 (11.5 to 37.0)

13.7 (7.5 to 25.3)

16.3 (7.7 to 34.5)

15.4 (7.8 to 30.4)

16.3 (8.3 to 32.3)

5.3 (4.7 to 6.0)

7.5 (5.6 to 10.1)

16.6 (9.7 to 28.3)

16.3 (8.0 to 33.5)

15.9 (9.6 to 26.2)

8.4 (5.6 to 12.6)

7.9 (5.2 to 12.1)

49.0 (18.3 to 131.4)

5.0 (5.0 to 5.0)

5.3 (4.7 to 6.0)

7.1 (4.9 to 10.2)

7 days after Boost Immunization (Day 29)

9999 (9999 to 9999)

55.0 (32.5 to 93.1)

9999 (9999 to 9999)

181.5 (107.5 to 306.3)

9999 (9999 to 9999)

320.0 (183.6 to 557.7)

169.5 (70.3 to 408.7)

207.5 (94.0 to 458.0)

38.9 (16.1 to 93.5)

134.5 (82.2 to 220.1)

40.0 (-999 to 999)

213.6 (114.7 to 397.7)

329.4 (203.2 to 533.9)

127.0 (79.2 to 203.7)

164.7 (77.0 to 352.0)

678.1 (395.9 to 1161.2)

5.0 (5.0 to 5.0)

5.3 (4.7 to 6.0)

8.0 (4.8 to 13.4)

21 days after Boost Immunization (Day 43)

5.0 (5.0 to 5.0)

8.7 (3.8 to 19.8)

5.3 (4.6 to 6.1)

69.2 (33.0 to 145.4)

95.1 (47.0 to 192.7)

62.2 (30.4 to 127.0)

160.0 (90.3 to 283.6)

184.9 (96.8 to 353.0)

282.1 (136.8 to 581.6)

8.9 (6.1 to 13.0)

293.4 (179.9 to 478.5)

95.1 (42.3 to 214.0)

134.5 (66.8 to 270.8)

49.9 (26.9 to 92.6)

109.9 (71.1 to 169.8)

187.3 (119.9 to 292.6)

164.7 (89.3 to 303.6)

300.5 (182.7 to 494.1)

134.5 (85.4 to 214.1)

169.5 (115.3 to 249.2)

452.5 (255.6 to 801.1)

5.1 (4.8 to 5.5)

5.6 (4.9 to 6.5)

5.7 (4.8 to 6.6)

6.0 (4.6 to 8.0)

28 days after Boost Immunization (Day 50)

5.0 (-999 to 999)

9999 (9999 to 9999)

80.0 (36.1 to 177.5)

9999 (9999 to 9999)

82.3 (37.4 to 181.1)

9999 (9999 to 9999)

226.3 (120.5 to 424.8)

89.8 (37.5 to 214.9)

95.1 (50.9 to 178.0)

36.4 (20.8 to 63.8)

67.3 (35.7 to 126.7)

190.3 (118.4 to 305.7)

160.0 (84.6 to 302.5)

213.6 (148.8 to 306.6)

127.0 (75.7 to 213.0)

132.4 (91.8 to 191.0)

391.7 (229.4 to 668.8)

5.0 (5.0 to 5.0)

5.9 (5.0 to 7.1)

5.0 (5.0 to 5.0)

5.3 (4.7 to 6.0)

63 days after Boost Immunization (Day 85)

5.0 (5.0 to 5.0)

7.5 (3.9 to 14.5)

5.0 (5.0 to 5.0)

25.9 (14.6 to 46.0)

31.7 (14.5 to 69.4)

40.0 (21.1 to 76.0)

134.5 (70.0 to 258.6)

102.9 (58.1 to 182.2)

120.5 (56.1 to 258.7)

7.7 (5.2 to 11.4)

46.2 (25.4 to 84.0)

33.6 (16.6 to 68.1)

69.2 (33.8 to 142.0)

36.4 (19.3 to 68.6)

33.6 (19.9 to 57.0)

145.6 (85.5 to 247.8)

146.7 (80.9 to 265.9)

160.0 (97.4 to 263.0)

21.8 (12.1 to 39.2)

27.4 (17.5 to 42.9)

80.0 (39.1 to 163.5)

5.6 (5.0 to 6.3)

5.0 (5.0 to 5.0)

5.2 (4.7 to 5.8)

162 days after Boost Immunization (Day 184)

5.0 (5.0 to 5.0)

6.9 (3.4 to 13.8)

5.0 (5.0 to 5.0)

10.0 (6.1 to 16.4)

15.0 (9.0 to 24.8)

13.7 (8.8 to 21.4)

27.4 (14.0 to 53.6)

29.2 (13.9 to 61.2)

56.6 (22.3 to 143.6)

5.2 (4.8 to 5.5)

16.8 (10.0 to 28.2)

19.4 (10.7 to 35.1)

65.4 (31.7 to 134.8)

8.5 (5.6 to 13.0)

11.2 (7.8 to 16.2)

21.3 (12.2 to 37.3)

54.8 (31.5 to 95.5)

38.9 (20.6 to 73.2)

26.7 (14.1 to 50.4)

15.5 (11.8 to 20.5)

58.4 (30.6 to 111.3)

5.0 (5.0 to 5.0)

5.8 (4.2 to 7.9)

10.4 (3.4 to 31.5)

No statistical analyses for this end point

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Top of page

End point title

Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B) ^[7]

End point description

At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one postbaseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as Day 29 and/or Day 50 were scheduled before approval of protocol version 7 which implemented these visits. 999 indicates confidence interval not calculated as values of at least 3 participants were not available.

End point type

Secondary

End point timeframe

Up to 183 days following Dose 1

Notes
[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162a1, BNT162b1, BNT162b2 Dose Ranging, and BNT162c2 Prime/Boost Cohorts.

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

Number of subjects analysed

Units: Titer

geometric mean (confidence interval 95%)

7 days after Prime Immunization (Day 8)

1.0 (1.0 to 1.0)

1.2 (0.8 to 1.7)

1.0 (1.0 to 1.0)

21 days after Prime Immunization (Day 22)

1.0 (1.0 to 1.0)

2.0 (1.2 to 3.3)

1.4 (0.9 to 2.1)

2.0 (1.1 to 3.7)

2.3 (1.2 to 4.4)

5.8 (2.7 to 12.6)

4.0 (2.2 to 7.3)

2.7 (1.5 to 5.1)

3.3 (1.5 to 6.9)

3.1 (1.6 to 6.1)

3.3 (1.7 to 6.5)

1.1 (0.9 to 1.2)

1.5 (1.1 to 2.0)

3.3 (1.9 to 5.7)

3.3 (1.6 to 6.7)

3.2 (1.9 to 5.2)

1.7 (1.1 to 2.5)

1.6 (1.0 to 2.4)

7.1 (4.3 to 11.9)

1.0 (1.0 to 1.0)

1.1 (0.9 to 1.2)

1.4 (1.0 to 2.0)

7 days after Boost Immunization (Day 29)

9999 (9999 to 9999)

11.0 (6.5 to 18.6)

9999 (9999 to 9999)

36.3 (21.5 to 61.3)

9999 (9999 to 9999)

64.0 (36.7 to 111.5)

33.9 (14.1 to 81.7)

41.5 (18.8 to 91.6)

7.8 (3.2 to 18.7)

26.9 (16.4 to 44.0)

8.0 (-999 to 999)

42.7 (22.9 to 79.5)

65.9 (40.6 to 106.8)

25.4 (15.8 to 40.7)

32.9 (15.4 to 70.4)

98.7 (62.2 to 156.5)

1.0 (1.0 to 1.0)

1.1 (0.9 to 1.2)

1.6 (1.0 to 2.7)

21 days after Boost Immunization (Day 43)

1.0 (1.0 to 1.0)

1.7 (0.8 to 4.0)

1.1 (0.9 to 1.2)

13.8 (6.6 to 29.1)

19.0 (9.4 to 38.5)

12.4 (6.1 to 25.4)

32.0 (18.1 to 56.7)

37.0 (19.4 to 70.6)

54.7 (26.5 to 112.8)

1.8 (1.2 to 2.6)

58.7 (36.0 to 95.7)

19.0 (8.5 to 42.8)

26.9 (13.4 to 54.2)

10.0 (5.4 to 18.5)

22.0 (14.2 to 34.0)

37.5 (24.0 to 58.5)

32.9 (17.9 to 60.7)

60.1 (36.5 to 98.8)

26.9 (16.9 to 42.8)

33.9 (23.1 to 49.8)

65.9 (45.5 to 95.3)

1.0 (1.0 to 1.1)

1.1 (1.0 to 1.3)

1.2 (0.9 to 1.6)

28 days after Boost Immunization (Day 50)

1.0 (-999 to 999)

9999 (9999 to 9999)

16.0 (7.2 to 35.5)

9999 (9999 to 9999)

16.5 (7.5 to 36.2)

9999 (9999 to 9999)

45.3 (24.1 to 85.0)

18.0 (7.5 to 43.0)

19.0 (10.2 to 35.6)

7.3 (4.2 to 12.8)

13.5 (7.1 to 25.3)

38.1 (23.7 to 61.1)

32.0 (16.9 to 60.5)

42.7 (29.8 to 61.3)

25.4 (15.1 to 42.6)

26.5 (18.4 to 38.2)

57.0 (38.6 to 84.3)

1.0 (1.0 to 1.0)

1.2 (1.0 to 1.4)

1.0 (1.0 to 1.0)

1.1 (0.9 to 1.2)

63 days after Boost Immunization (Day 85)

1.0 (1.0 to 1.0)

1.5 (0.8 to 2.9)

1.0 (1.0 to 1.0)

5.2 (2.9 to 9.2)

6.3 (2.9 to 13.9)

8.0 (4.2 to 15.2)

26.9 (14.0 to 51.7)

20.6 (11.6 to 36.4)

23.4 (10.8 to 50.4)

1.5 (1.0 to 2.3)

9.2 (5.1 to 16.8)

6.7 (3.3 to 13.6)

13.8 (6.8 to 28.4)

7.3 (3.9 to 13.7)

6.7 (4.0 to 11.4)

29.1 (17.1 to 49.6)

29.3 (16.2 to 53.2)

32.0 (19.5 to 52.6)

4.4 (2.4 to 7.8)

5.5 (3.5 to 8.6)

11.6 (7.3 to 18.7)

1.1 (1.0 to 1.3)

1.0 (1.0 to 1.0)

1.0 (0.9 to 1.2)

162 days after Boost Immunization (Day 184)

1.0 (1.0 to 1.0)

1.4 (0.7 to 2.8)

1.0 (1.0 to 1.0)

2.0 (1.2 to 3.3)

3.0 (1.8 to 5.0)

2.7 (1.8 to 4.3)

5.5 (2.8 to 10.7)

5.8 (2.8 to 12.2)

11.0 (4.3 to 28.2)

1.0 (1.0 to 1.1)

3.4 (2.0 to 5.6)

3.9 (2.1 to 7.0)

13.1 (6.3 to 27.0)

1.7 (1.1 to 2.6)

2.2 (1.6 to 3.2)

4.3 (2.4 to 7.5)

11.0 (6.3 to 19.1)

7.8 (4.1 to 14.6)

5.3 (2.8 to 10.1)

3.1 (2.4 to 4.1)

11.7 (6.1 to 22.3)

1.0 (1.0 to 1.0)

1.2 (0.8 to 1.6)

2.1 (0.7 to 6.3)

No statistical analyses for this end point

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Top of page

End point title

Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B) ^[8]

End point description

End point type

Secondary

End point timeframe

Up to 183 days following Dose 1

Notes
[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162a1, BNT162b1, BNT162b2 Dose Ranging, and BNT162c2 Prime/Boost Cohorts.

End point values	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg
Number of subjects analysed	12	12	6	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
Units: Participants
7 days after Prime Immunization (Day 8)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
21 days after Prime Immunization (Day 22)	0	0	0	2	1	3	3	7	7	6	5	6	3	0	0	7	5	6	2	2	10	0	0	0	1
7 days after Boost Immunization (Day 29)	9999	9999	9999	9999	11	9999	11	9999	9999	9999	12	12	11	7	12	1	12	12	12	12	12	0	0	0	2
21 days after Boost Immunization (Day 43)	0	2	0	10	11	9	10	12	11	3	12	11	12	9	12	11	12	11	12	12	12	0	0	0	0
28 days after Boost Immunization (Day 50)	0	9999	9999	9999	11	9999	11	9999	9999	9999	12	11	12	9	11	12	12	12	12	11	12	0	0	0	0
63 days after Boost Immunization (Day 85)	0	2	0	9	8	9	10	11	11	1	10	8	10	8	9	11	12	12	8	7	12	0	0	0	0
162 days after Boost Immunization (Day 184)	0	1	0	3	6	4	7	8	10	0	5	7	10	3	2	6	10	11	7	4	10	0	0	1	2

No statistical analyses for this end point

Secondary: Functional Antibody Responses (Titers) for BNT162c2 (SD)

Top of page

End point title

Functional Antibody Responses (Titers) for BNT162c2 (SD) ^[9]

End point description

At Day 1 (Baseline) and at 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one postbaseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as Day 29 of cohort 0.1 μg was scheduled before approval of protocol version 7 which implemented this visit.

End point type

Secondary

End point timeframe

Up to 183 days following Dose 1

Notes
[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162c2 single dose cohorts.

End point values	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Number of subjects analysed	12	12	12	12
Units: Titer
geometric mean (confidence interval 95%)
Pre-Prime Immunization (Day 1)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)
7 days after Prime Immunization (Day 8)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)
21 days after Prime Immunization (Day 22)	5.1 (4.8 to 5.5)	5.1 (4.8 to 5.5)	5.3 (4.7 to 6.0)	5.5 (4.8 to 6.3)
28 days after Prime Immunization (Day 29)	9999 (9999 to 9999)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.2 (4.8 to 5.6)
42 days after Prime Immunization (Day 43)	5.1 (4.8 to 5.5)	5.1 (4.8 to 5.5)	5.5 (4.5 to 6.6)	5.1 (4.8 to 5.5)
84 days after Prime Immunization (Day 85)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	6.0 (4.0 to 9.2)	5.0 (5.0 to 5.0)
183 days after Prime Immunization (Day 184)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.5 (4.5 to 6.8)	6.4 (3.7 to 11.3)

No statistical analyses for this end point

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

Top of page

End point title

Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD) ^[10]

End point description

At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one postbaseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as Day 29 of cohort 0.1 μg was scheduled before approval of protocol version 7 which implemented this visit.

End point type

Secondary

End point timeframe

Up to 183 days following Dose 1

Notes
[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162c2 single dose cohorts.

End point values	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Number of subjects analysed	12	12	12	12
Units: Titer
geometric mean (confidence interval 95%)
7 days after Prime Immunization (Day 8)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)
21 days after Prime Immunization (Day 22)	1.0 (1.0 to 1.1)	1.0 (1.0 to 1.1)	1.1 (0.9 to 1.2)	1.1 (1.0 to 1.3)
28 days after Prime Immunization (Day 29)	9999 (9999 to 9999)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.1)
42 days after Prime Immunization (Day 43)	1.0 (1.0 to 1.1)	1.0 (1.0 to 1.1)	1.1 (0.9 to 1.3)	1.0 (1.0 to 1.1)
84 days after Prime Immunization (Day 85)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.2 (0.8 to 1.8)	1.0 (1.0 to 1.0)
183 days after Prime Immunization (Day 184)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.1 (0.9 to 1.4)	1.3 (0.7 to 2.3)

No statistical analyses for this end point

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

Top of page

End point title

Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD) ^[11]

End point description

At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as Day 29 of cohort 0.1 μg was scheduled before approval of protocol version 7 which implemented this visit.

End point type

Secondary

End point timeframe

Up to 183 days following Dose 1

Notes
[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162c2 single dose cohorts.

End point values	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Number of subjects analysed	12	12	12	12
Units: Participants
7 days after Prime Immunization (Day 8)	0	0	0	0
21 days after Prime Immunization (Day 22)	0	0	0	0
28 days after Prime Immunization (Day 29)	9999	0	0	0
42 days after Prime Immunization (Day 43)	0	0	0	0
84 days after Prime Immunization (Day 85)	0	0	1	0
183 days after Prime Immunization (Day 184)	0	0	0	1

No statistical analyses for this end point

Secondary: Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Top of page

End point title

Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B) ^[12]

End point description

At Day 1 (Baseline) and at 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as, according to the protocol, Day 15 assessment was only performed for Cohort 14, and Day 36, Day 43, Day 85, and Day 365 assessments were only performed for Cohorts 11, 12, and 13. 999 indicates confidence interval not calculated as values of at least 3 participants were not available. 99999 indicates data not available as all participants crossed-over to study BNT162-14 before reaching Day 365 or were discontinued due to the reception of a non-trial vaccination.

End point type

Secondary

End point timeframe

Up to 1 year following Dose 1

Notes
[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162b2 Expansion Cohorts.

End point values	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14
Number of subjects analysed	15	15	30	90	20
Units: Titer
geometric mean (confidence interval 95%)
Pre-Prime Immunization (Day 1)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.1 (4.9 to 5.3)	5.0 (5.0 to 5.0)
7 days after Prime Immunization (Day 8)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	5.4 (4.8 to 6.0)	5.3 (4.7 to 6.1)	6.6 (4.2 to 10.4)
14 days after Prime Immunization (Day 15)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9.5 (4.8 to 18.7)
21 days after Prime Immunization (Day 22)	17.4 (9.8 to 30.9)	5.2 (4.7 to 5.8)	5.7 (4.8 to 6.8)	21.9 (17.5 to 27.3)	17.9 (9.5 to 33.7)
7 days after Boost Immunization (Day 29)	167.6 (112.0 to 250.7)	12.0 (5.5 to 26.4)	30.7 (21.3 to 44.1)	348.6 (270.8 to 448.8)	286.8 (183.1 to 449.4)
14 days after Boost Immunization (Day 36)	206.3 (116.8 to 364.3)	11.5 (5.3 to 24.8)	149.3 (104.0 to 214.4)	379.1 (306.0 to 469.6)	9999 (9999 to 9999)
21 days after Boost Immunization (Day 43)	167.6 (93.8 to 299.2)	9.8 (4.8 to 19.7)	119.9 (81.5 to 176.4)	307.8 (250.0 to 378.9)	9999 (9999 to 9999)
28 days after Boost Immunization (Day 50)	136.1 (76.2 to 243.0)	11.0 (5.1 to 23.7)	87.7 (62.3 to 123.7)	266.5 (215.9 to 328.8)	103.3 (70.8 to 150.6)
63 days after Boost Immunization (Day 85)	50.4 (30.7 to 82.7)	8.3 (5.0 to 13.7)	79.1 (56.7 to 110.2)	99.9 (81.3 to 122.7)	9999 (9999 to 9999)
162 days after Boost Immunization (Day 184)	27.0 (16.3 to 44.6)	11.9 (4.0 to 35.3)	19.2 (11.9 to 30.9)	29.5 (23.5 to 37.1)	49.8 (33.3 to 74.4)
343 days after Boost Immunization (Day 365)	99999 (99999 to 99999)	99999 (99999 to 99999)	7.1 (-999 to 999)	30.2 (11.7 to 78.2)	9999 (9999 to 9999)

No statistical analyses for this end point

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Top of page

End point title

Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B) ^[13]

End point description

At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization). Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. 9999 indicates data not available as, according to the protocol, Day 15 assessment was only performed for Cohort 14, and Day 36, Day 43, Day 85, and Day 365 assessments were only performed for Cohorts 11, 12, and 13. 999 indicates confidence interval not calculated as values of at least 3 participants were not available. 99999 indicates data not available as all participants crossed-over to study BNT162-14 before reaching Day 365 or were discontinued due to the reception of a non-trial vaccination.

End point type

Secondary

End point timeframe

Up to 1 year following Dose 1

Notes
[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162b2 Expansion Cohorts.

End point values	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14
Number of subjects analysed	15	15	30	90	20
Units: Titer
geometric mean (confidence interval 95%)
7 days after Prime Immunization (Day 8)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.1 (1.0 to 1.2)	1.0 (1.0 to 1.1)	1.3 (0.8 to 2.1)
14 days after Prime Immunization (Day 15)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	1.9 (1.0 to 3.7)
21 days after Prime Immunization (Day 22)	3.5 (2.0 to 6.2)	1.0 (0.9 to 1.2)	1.1 (1.0 to 1.4)	4.3 (3.5 to 5.3)	3.6 (1.9 to 6.7)
7 days after Boost Immunization (Day 29)	33.5 (22.4 to 50.1)	2.4 (1.1 to 5.3)	6.1 (4.3 to 8.8)	68.4 (53.3 to 87.7)	57.4 (36.6 to 89.9)
14 days after Boost Immunization (Day 36)	41.3 (23.4 to 72.9)	2.3 (1.1 to 5.0)	29.9 (20.8 to 42.9)	74.3 (60.2 to 91.8)	9999 (9999 to 9999)
21 days after Boost Immunization (Day 43)	33.5 (18.8 to 59.8)	2.0 (1.0 to 3.9)	24.0 (16.3 to 35.3)	60.4 (49.2 to 74.1)	9999 (9999 to 9999)
28 days after Boost Immunization (Day 50)	27.2 (15.2 to 48.6)	2.2 (1.0 to 4.7)	17.5 (12.5 to 24.7)	52.3 (42.7 to 64.0)	20.7 (14.2 to 30.1)
63 days after Boost Immunization (Day 85)	10.1 (6.1 to 16.5)	1.7 (1.0 to 2.7)	15.8 (11.3 to 22.0)	19.6 (16.0 to 23.9)	9999 (9999 to 9999)
162 days after Boost Immunization (Day 184)	5.4 (3.3 to 8.9)	2.4 (0.8 to 7.1)	3.8 (2.4 to 6.2)	5.8 (4.6 to 7.2)	10.0 (6.7 to 14.9)
343 days after Boost Immunization (Day 365)	99999 (99999 to 99999)	99999 (99999 to 99999)	1.4 (-999 to 999)	5.4 (2.1 to 13.8)	99999 (99999 to 99999)

No statistical analyses for this end point

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Top of page

End point title

Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B) ^[14]

End point description

End point type

Secondary

End point timeframe

Up to 1 year following Dose 1

Notes
[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only reports data for the BNT162b2 Expansion Cohorts.

End point values	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14
Number of subjects analysed	15	15	30	90	20
Units: Participants
7 days after Prime Immunization (Day 8)	0	0	1	1	2
14 days after Prime Immunization (Day 15)	9999	9999	9999	9999	4
21 days after Prime Immunization (Day 22)	7	0	1	54	9
7 days after Boost Immunization (Day 29)	15	4	22	88	19
14 days after Boost Immunization (Day 36)	15	4	30	88	9999
21 days after Boost Immunization (Day 43)	15	3	29	89	9999
28 days after Boost Immunization (Day 50)	15	4	30	89	19
63 days after Boost Immunization (Day 85)	13	2	28	84	9999
162 days after Boost Immunization (Day 184)	12	3	12	61	18
343 days after Boost Immunization (Day 365)	99999	99999	0	10	99999

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

Local reactions/systemic events: within 7 days after each IMP dose; SAEs: from Day 1 (Dose 1 [Prime]) up to Day 387 (approximately 12 months after Dose 2 [Boost]); other AEs: see below in section 'AE reporting additional description'.

Adverse event reporting additional description

Timeframe for AE reporting continued: Other AEs in participants with Dose 2: All AEs from Day 1 up to Day 50 and in addition if assessed as IMP-related from Day 50 up to Day 387; Other AEs in participants without Dose 2: All AEs from Day 1 up to Day 29 and in addition if assessed as IMP-related from Day 29 up to Day 387.

Assessment type

Systematic

Dictionary name

MedDRA

Dictionary version

23.0

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen).

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162a1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee [SRC]).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the SRC).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

Reporting group description

BNT162b1: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), expansion cohort (Cohort 13). ICP = Immunocompromised participants.

Reporting group title

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen), expansion cohort (Cohort 13). ICP = Immunocompromised participants, PT = post-transplant.

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), alternative posology dose group expansion cohort (Cohort 11). .

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12

Reporting group description

Reporting group title

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14

Reporting group description

BNT162b2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen), B-cell immune response dose group expansion cohort (C14 = Cohort 14).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (P/B regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (single dose [SD] regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

Reporting group title

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD

Reporting group description

BNT162c2: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (SD regimen).

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg

BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg

BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg

BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg

BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg

BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg

BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV

BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT

BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12

BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD

BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD

BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD

Total subjects affected by serious adverse events

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

2 / 12 (16.67%)

0 / 12 (0.00%)

1 / 12 (8.33%)

3 / 12 (25.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

3 / 15 (20.00%)

0 / 30 (0.00%)

3 / 90 (3.33%)

1 / 20 (5.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

number of deaths (all causes)

number of deaths resulting from adverse events

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Oesophageal carcinoma

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Injury, poisoning and procedural complications

Ankle fracture

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Femur fracture

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

1 / 90 (1.11%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Surgical and medical procedures

Hip arthroplasty

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

1 / 90 (1.11%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Cardiac disorders

Myocardial infarction

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

1 / 90 (1.11%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

0 / 1

0 / 0

Nervous system disorders

Syncope

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

General disorders and administration site conditions

Pelvic mass

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Gastrointestinal disorders

Diverticulum intestinal haemorrhagic

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Inguinal hernia

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Umbilical hernia

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

1 / 20 (5.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Infections and infestations

Cystitis

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

1 / 90 (1.11%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Urinary tract infection

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

3 / 15 (20.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 3

0 / 0

deaths causally related to treatment / all

0 / 0

COVID-19

subjects affected / exposed

0 / 12 (0.00%)

0 / 6 (0.00%)

0 / 12 (0.00%)

0 / 15 (0.00%)

0 / 30 (0.00%)

0 / 90 (0.00%)

0 / 20 (0.00%)

0 / 12 (0.00%)

1 / 12 (8.33%)

occurrences causally related to treatment / all

0 / 0

0 / 1

deaths causally related to treatment / all

0 / 0

Frequency threshold for reporting non-serious adverse events: 0%

Non-serious adverse events	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg	BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg	BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg	BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg HIV	BNT162b2 - Part A ICP Aged 18 to 85 Years - 30 μg PT	BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C12	BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg C14	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg SD	BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg SD
Total subjects affected by non serious adverse events
subjects affected / exposed	9 / 12 (75.00%)	9 / 12 (75.00%)	5 / 6 (83.33%)	9 / 12 (75.00%)	2 / 12 (16.67%)	12 / 12 (100.00%)	6 / 12 (50.00%)	12 / 12 (100.00%)	12 / 12 (100.00%)	12 / 12 (100.00%)	3 / 12 (25.00%)	4 / 12 (33.33%)	9 / 12 (75.00%)	8 / 12 (66.67%)	7 / 12 (58.33%)	12 / 12 (100.00%)	10 / 12 (83.33%)	11 / 12 (91.67%)	4 / 12 (33.33%)	7 / 12 (58.33%)	4 / 12 (33.33%)	3 / 15 (20.00%)	11 / 15 (73.33%)	13 / 30 (43.33%)	48 / 90 (53.33%)	9 / 20 (45.00%)	4 / 12 (33.33%)	5 / 12 (41.67%)	4 / 12 (33.33%)	2 / 12 (16.67%)	10 / 12 (83.33%)	9 / 12 (75.00%)	5 / 12 (41.67%)	11 / 12 (91.67%)
Vascular disorders
Hot flush
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Haematoma
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	1 / 15 (6.67%)	0 / 30 (0.00%)	1 / 90 (1.11%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0
Hypertension
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	5 / 90 (5.56%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0	0	0
Hypotension
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	1 / 15 (6.67%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Systolic hypertension
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	1 / 30 (3.33%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Diastolic hypotension
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 6 (16.67%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surgical and medical procedures
Dental care
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	1 / 90 (1.11%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Mole excision
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Papilloma excision
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
General disorders and administration site conditions
Chills
subjects affected / exposed	1 / 12 (8.33%)	1 / 12 (8.33%)	0 / 6 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	1 / 30 (3.33%)	2 / 90 (2.22%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences all number	1	1	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0
Fatigue
subjects affected / exposed	1 / 12 (8.33%)	1 / 12 (8.33%)	1 / 6 (16.67%)	7 / 12 (58.33%)	0 / 12 (0.00%)	6 / 12 (50.00%)	0 / 12 (0.00%)	5 / 12 (41.67%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	2 / 12 (16.67%)	1 / 12 (8.33%)	4 / 12 (33.33%)	5 / 12 (41.67%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	2 / 90 (2.22%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	3 / 12 (25.00%)	4 / 12 (33.33%)	2 / 12 (16.67%)	3 / 12 (25.00%)
occurrences all number	1	3	1	7	0	7	0	7	1	0	0	0	0	2	1	5	6	1	0	0	0	0	0	0	2	0	0	0	0	0	3	5	2	3
Feeling hot
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Influenza like illness
subjects affected / exposed	3 / 12 (25.00%)	8 / 12 (66.67%)	1 / 6 (16.67%)	4 / 12 (33.33%)	0 / 12 (0.00%)	8 / 12 (66.67%)	0 / 12 (0.00%)	10 / 12 (83.33%)	11 / 12 (91.67%)	10 / 12 (83.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	2 / 12 (16.67%)	0 / 12 (0.00%)	7 / 12 (58.33%)	2 / 12 (16.67%)	4 / 12 (33.33%)	2 / 12 (16.67%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	2 / 15 (13.33%)	0 / 30 (0.00%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	2 / 12 (16.67%)	2 / 12 (16.67%)	0 / 12 (0.00%)	2 / 12 (16.67%)
occurrences all number	5	14	1	7	0	8	0	16	21	10	0	0	0	3	0	7	2	4	2	0	0	0	2	0	0	0	0	0	0	1	2	2	0	2
Injection site reaction
subjects affected / exposed	9 / 12 (75.00%)	8 / 12 (66.67%)	1 / 6 (16.67%)	4 / 12 (33.33%)	0 / 12 (0.00%)	8 / 12 (66.67%)	0 / 12 (0.00%)	11 / 12 (91.67%)	12 / 12 (100.00%)	6 / 12 (50.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	2 / 12 (16.67%)	0 / 12 (0.00%)	11 / 12 (91.67%)	9 / 12 (75.00%)	10 / 12 (83.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	0 / 15 (0.00%)	1 / 30 (3.33%)	0 / 90 (0.00%)	0 / 20 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	1 / 12 (8.33%)	2 / 12 (16.67%)	3 / 12 (25.00%)	9 / 12 (75.00%)
occurrences all number	10	15	1	7	0	11	0	19	20	6	0	0	0	2	0	21	9	10	0	0	0	0	0	2	0	0	0	0	2	0	1	2	3	9
Pyrexia
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 6 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)	2 / 12 (16.67%)	2 / 12 (16.67%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 15 (0.00%)	1 / 15 (6.67%)	0 / 30 (0.00%)	2 / 90 (2.22%)	0 / 20 (0.00%)	0 / 12 (0.00%)

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Clinical Trial Results: A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose

Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose

Primary: Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose

Primary: Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose

Primary: The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1

Primary: The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1

Primary: The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)

Primary: The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)

Secondary: Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Secondary: Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

Secondary: Functional Antibody Responses (Titers) for BNT162c2 (SD)

Secondary: Functional Antibody Responses (Titers) for BNT162c2 (SD)

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

Secondary: Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Secondary: Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Secondary: Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13 and 14; P/B)

Adverse events

Clinical Trial Results:
A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults